Ginkgo Bioworks, the once-high-flying Boston life sciences firm, said it has notified 158 employees that they will be laid off and expects to announce another batch of layoffs next week.

Ginkgo Bioworks has been busy, announcing not just one but three acquisitions and the creation of a network backed by 25 partners that will offer ‘end-to-end’ services to R&D clients.

Ginkgo Bioworks faces ongoing revenue declines and high cash burn, despite cost-cutting efforts and partnerships with major firms like Pfizer and Merck. The company's Q3 2024 revenue was inflated ...

TD Cowen analyst Brendan Smith raised the firm’s price target on Ginkgo Bioworks (DNA) to $16 from $10 and keeps a Buy rating on the shares.

Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics BOSTON, Jan. 13, 2025 ...

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial ...

北京时间2025年01月17日01时55分，Ginkgo Bioworks Holdings, Inc.（DNA.us）股票出现波动，股价快速上涨5.00%。截至发稿，该股报9.77美元 ...

Reshma Shetty is the president, chief operating officer, and cofounder of Ginkgo Bioworks, which went public in 2021 in a merger with a so-called blank-check company that generated more than $1.6 ...

What's Going On With Ginkgo Bioworks Stock This Week? Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares continue to trade higher after rising nearly 10% on Tuesday. Here's a look at what's going on.